NDA 020083 · Janssen Pharms
Sporanox
Itraconazole · Oral · Azole Antifungal
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Jul 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Sep 11, 1992
Approved uses
2
Original approval plus efficacy supplements
Registered trials
507
27 Phase 3, 40 recruiting
FAERS reports
11,784
10,489 serious, 2,277 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
BOXED WARNING Congestive Heart Failure, Cardiac Effects and Drug Interactions Congestive Heart Failure and Cardiac Effects SPORANOX ® (itraconazole) Capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of SPORANOX ® Capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen. (See CONTRAINDICATIONS , WARNINGS , PRECAUTIONS: Drug Interactions , ADVERSE REACTIONS: Postmarketing Experience , and CLINICAL PHARMACOLOGY: Special Populations for more information.) Drug Interactions Coadministration of a number of CYP3A4 substrates are contraindicated with SPORANOX ® . Some examples of...
What it is approved for
From the label in effect Jul 13, 2026.
INDICATIONS AND USAGE SPORANOX ® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. SPORANOX ® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Postmarketing Experience for more information.) Description of Clinical Studies Blastomycosis Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within...
Mechanism: Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 1994 Supplement 4 · Efficacy
- Sep 11, 1992 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- SPORANOX · ITRACONAZOLE 100MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Itraconazole" as an intervention, any sponsor and status, largest first.
BioNTech SEIndustry
NCT07070232 · 1,438 participants (planned) · Start Aug 12, 2025 · Primary completion Mar 2028
Drug: BNT326; Pumitamig and 2 more · For: Advanced Solid Tumor
Sites: Phoenix, Arizona; San Francisco, California; Hartford, Connecticut · 79 sites in all
- Itraconazole Tablets Vs. Itraconazole Capsules vs. Placebo in Onychomycosis of the Toenail.Pivotal-lookingCompleted
Stiefel, a GSK CompanyIndustry
NCT00356915 · 1,381 participants · Start Jul 2006 · Primary completion Oct 2008
Drug: Itraconazole 100mg capsules; Itraconazole 200mg tablets and 1 more · For: Onychomycosis
Sites: Birmingham, Alabama; Tuscon, Arizona; Hot Springs, Arkansas · 68 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Recruiting
GenmabIndustry
NCT05579366 · 952 participants (planned) · Start Dec 7, 2022 · Primary completion Dec 2028
Drug: Rina-S; Carboplatin and 4 more · For: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma and 13 more
Sites: Phoenix, Arizona; Tucson, Arizona; Los Angeles, California · 67 sites in all
DualityBio Inc.Industry
NCT05914116 · 862 participants (planned) · Start Aug 17, 2023 · Primary completion Dec 2027
Drug: DB-1311; Lopinavir and Ritonavir Tablets and 3 more · For: Advanced Solid Tumors
Sites: Tucson, Arizona; Los Angeles, California; Santa Monica, California · 107 sites in all
Nuvalent Inc.Industry
NCT05384626 · 840 participants (planned) · Start Jun 9, 2022 · Primary completion Dec 2027
Drug: Neladalkib (NVL-655); Midazolam and 2 more · For: Locally Advanced Solid Tumor; Metastatic Solid Tumor
Sites: Orange, California; Sacramento, California; Stanford, California · 74 sites in all
- A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsPivotal-lookingRecruiting
DualityBio Inc.Industry
NCT05150691 · 796 participants (planned) · Start Jan 31, 2022 · Primary completion Aug 2027
Drug: DB-1303/BNT323; Pertuzumab Injection and 2 more · For: HER2-positive Advanced Solid Tumor
Sites: Cerritos, California; Los Angeles, California; San Diego, California · 102 sites in all
- Anticoagulation in ICH Survivors for Stroke Prevention and RecoveryPivotal-lookingRecruiting
Yale UniversityAcademic, hospital or other
NCT03907046 · 700 participants (planned) · Start Jan 28, 2020 · Primary completion Apr 2027
Drug: Apixaban; Aspirin · For: Intracerebral Hemorrhage; Atrial Fibrillation
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 187 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug interaction1,191
- drug ineffective1,144
- off label use632
- pyrexia589
- dyspnoea493
- pneumonia484
- nausea468
- diarrhoea404
- condition aggravated400
- febrile neutropenia373
- fatigue351
- rash310
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 277 |
| 2005 | 192 |
| 2006 | 219 |
| 2007 | 254 |
| 2008 | 291 |
| 2009 | 408 |
| 2010 | 361 |
| 2011 | 621 |
| 2012 | 587 |
| 2013 | 409 |
| 2014 | 373 |
| 2015 | 610 |
| 2016 | 474 |
| 2017 | 517 |
| 2018 | 703 |
| 2019 | 826 |
| 2020 | 868 |
| 2021 | 782 |
| 2022 | 676 |
| 2023 | 676 |
| 2024 | 601 |
| 2025 | 566 |
| 2026 | 492 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Feb 27, 2026
Sporanox, Capsule, 100 mg (NDC 50458-290-01). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Feb 27, 2026
Sporanox, Capsule, 100 mg (NDC 10147-1700-3). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Feb 27, 2026
Sporanox, Capsule, 100 mg (NDC 50458-290-04). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Sporanox (Itraconazole)
2024 spending
$123K
Beneficiaries
26
82 claims
Per beneficiary
$4,730
$12.40 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $509,944 |
| 2021 | $247,250 |
| 2022 | $307,486 |
| 2023 | $196,502 |
| 2024 | $122,988 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA, Maertens J, Winston DJ, et al. · N Engl J Med 2007 · Comparative Study, Multicenter Study
- Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial.
Sehgal IS, Agarwal R, Dhooria S, et al. · Lancet Infect Dis 2026 · Randomized Controlled Trial, Comparative Study
- Coccidioidomycosis: clinical update.
Ampel NM, Wieden MA, Galgiani JN · Rev Infect Dis 1989 · Clinical Trial, Randomized Controlled Trial
- Itraconazole increases serum digoxin concentration.
Partanen J, Jalava KM, Neuvonen PJ · Pharmacol Toxicol 1996 · Clinical Trial, Randomized Controlled Trial
- Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
Marks DI, Pagliuca A, Kibbler CC, et al. · Br J Haematol 2011 · Multicenter Study, Randomized Controlled Trial
- Pharmacokinetic Drug Interaction Studies with Enzalutamide.
Gibbons JA, de Vries M, Krauwinkel W, et al. · Clin Pharmacokinet 2015 · Clinical Trial, Phase I, Clinical Trial, Phase III
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.